Cerus Corporation (NASDAQ:CERS) announced today that company management will present at the Morgan Stanley 11th Annual European MedTech Trip at 8:00 a.m. at the Hôtel Métropole in Brussels, Belgium on Tuesday, February 26. The meeting seeks to introduce U.S. institutional investors to medical technology companies with significant European operations.
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe and the Middle East. The company is also pursuing regulatory approvals in the United States and other countries. The INTERCEPT red blood cell system is currently in clinical development.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
William J. Dawson, 925-288-6053
Vice President, Finance & CFO
Vida Communication (On behalf of CERUS)
Stephanie Diaz, 415-675-7401